<\/p>\n
To fully appreciate why <\/span>World Diabetes Day<\/strong> is so important, it helps to lay out the severity of the mounting diabetes pandemic in its numbers \u2013 and they are pretty stark.<\/span><\/p>\n
Figures from 2021 show that around<\/span> 537 million adults between the ages of 20\u201379 years old live with diabetes worldwide \u2013 almost half of those are undiagnosed and 6.7 million could die as a result. (<\/span>IDF<\/span><\/a><\/span>)<\/span><\/p>\n
In 2020 world population numbers put the number of adults between 20\u201379 years old at approximately 5 billion<\/span>.<\/b> (<\/span>UN, World Population Prospects<\/span><\/span><\/a>)\u00a0<\/span><\/p>\n
In other words, roughly 10%+ of the global adult population have either type 1 (affecting <\/span>~10%<\/span><\/a><\/span>) or type 2 diabetes (affecting <\/span>~90%<\/span><\/span><\/a>). Those figures are not expected to fall over the next two decades, with diabetes projected to affect 643 million adults by 2030 and 783 million by 2045. (<\/span>IDF<\/span><\/span><\/a>) That is a 40% surge over the next 25 years.\u00a0<\/span><\/p>\n
Even more sobering is to remember that these numbers reflect only those with diabetes <\/span>right now<\/span><\/i>. When the risk factors associated with type 2 diabetes are considered, studies suggest that around 541 million adults are at increased risk of developing the disease. (<\/span>IDF<\/span><\/a><\/span>) (Type 1 diabetes cannot be prevented and the environmental triggers behind it are not yet fully understood).\u00a0<\/span><\/p>\n
READ:<\/strong> Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes<\/span><\/span><\/a><\/p>\n
Risk factors include:<\/span><\/p>\n
These figures demonstrate exactly why <\/span>World Diabetes Day on 14 November<\/strong> is crucial \u2013 to alert more people to the relative ease under which type 2 diabetes can (and does so more than ever) develop and the life-changing\/threatening complications it could pose.<\/span><\/p>\n
WATCH:<\/strong> Samuel Dagogo-Jack at ADA 2022 discusses highlights and hot topics in the field of diabetes<\/span><\/a><\/span><\/p>\n
READ:<\/strong> Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes<\/span><\/a><\/span><\/p>\n
WATCH: <\/strong>Diana Isaacs at ADCES 2022 talk about updates in diabetes technology<\/span><\/a>.<\/span><\/span><\/p>\n
Learn more by delving into our educational content on diabetes on <\/span>touchIMMUNOLOGY<\/span><\/span><\/a> and <\/span>touchENDOCRINOLOGY<\/span><\/span><\/a>.<\/span><\/p>\n
Alternatively, you can <\/span>get in touch<\/span><\/a><\/span> to find out how you could benefit from our educational activities.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"